Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Illumina’s Revenue Breakdown by Source from 2016 onwards, split between Sequencing and Microarray end-markets.
|Sources||Q3 2020||Q2 2021||Q3 2021||Contribution in Q3 2021|
(All figures are in millions, except percentages)
Illumina’s product range is divided into two categories: integrated sequencing and microarray systems, as well as smaller segments consumables and analytic tools, all of which are meant to speed up and simplify genetic study.
The technique of establishing the order of nucleotide bases (A, C, G, or T) in a DNA sample is known as DNA sequencing. The company’s sequencing platforms offer a family of systems that we feel set the bar for productivity, cost-effectiveness, and accuracy in the field of next-generation sequencing. Specific gene and area targeted resequencing along with RNA sequencing, whole-genome, exome, de novo, are all performed using the company’s systems.
The company’s DNA sequencing method is based on a patented reversible terminator-based sequencing chemistry known as sequencing by synthesis (SBS). Since their initial sequencing system was introduced in 2007, their technologies have lowered the cost of sequencing by a factor of 10,000. Furthermore, the sequencing time per Gb has decreased by a factor of 12,000 or more.
Illumina informatics tools support a number of operations, including sample preparation, instrument management and administration, and post-run analysis, for the company’s sequencing applications and clients. Customers may conduct sequencing runs, process and analyze raw genomic data, and generate meaningful conclusions using their BaseSpace Informatics Suite, which interacts directly with sequencing devices.
MicroArrays or arrays are applied in a variety of DNA and RNA analytic applications, such as SNP genotyping, CNV analysis, gene expression analysis, and methylation analysis, and may identify millions of known genetic markers on a single array. Arrays are the most common technique utilized in consumer genomics.
The BeadArray technology uses a patented manufacturing technique to mix tiny beads and a substrate to create arrays that can perform many tests at the same time. This allows for a novel, high-throughput, cost-effective, and adaptable approach to large-scale genetic variation and biological function study. BeadArray technology makes it possible for a high density of test sites per array and the ability to arrange arrays in numerous configurations and allows for high-throughput analysis.
The sale of products and services generates the majority portion of the company’s revenue. Sales of devices and consumables used in genetic analysis account for the majority of product income. Income from genotyping and sequencing services, instrument service contracts, development and licensing agreements, and cancer detection testing services associated with the GRAIL business make up the majority of service and other revenue.
Customers utilize the company’s products to investigate the genome at various degrees of sophistication, ranging from focused panels to whole-genome sequencing. Hundreds of thousands of customer-authored scientific articles have been published utilizing our technologies thanks to a broad and active Illumina user community. The firm is transforming the economics of genetic research by allowing previously unachievable undertakings and supporting clinical breakthroughs toward precision medicine through fast innovation.
Instruments and consumables are essentially what make up microarrays and other things. They account for the majority of the company’s product sales. They also provide a variety of services to their clients.
Illumina is a global leader in genetic and genomic analysis solutions based on sequencing and arrays. Their products and services are used by clients in a variety of industries, allowing genomic solutions to be used in research and clinical settings. Illumina was founded in April 1998 in California and renamed Illumina in Delaware in July 2000. The company executive offices are situated in San Diego, California. GRAIL, a healthcare business focused on the early detection of various malignancies, was bought by the corporation on August 18, 2021.
Did you like Illumina’s Revenue Breakdown by Source statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.